[ad_1]
NEW YORK, March 26, 2022 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ:AKBA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New Yorkand docketed under 22-cv-01411, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Full story available on Benzinga.com
[ad_2]
Source link
